US biopharma AbbVie has agreed a deal with Teneobio, a California-based biotech, to develop and commercialize an immunotherapeutic that targets B-cell maturation antigen (BCMA) for treating multiple myeloma, a type of blood cancer. Under the terms of the transaction, AbbVie will pay $90 million upfront to develop Teneobio’s TNB-383B, a bispecific antibody.
Original Article: AbbVie and Teneobio Link on Multiple Myeloma